Artificial intelligence (AI) is transforming healthcare, offering innovative solutions to complex challenges. Recent advancements show how AI is streamlining clinical trials and enabling better use of real-world data, creating significant opportunities for pharmaceutical companies and healthcare providers.
In clinical trials, AI-based solutions are driving market growth by improving efficiency and data analysis. Meanwhile, efforts to enhance access to real-world healthcare data are accelerating the development of reliable AI models. Together, these advancements are shaping the future of medicine.
Key Takeaways
Artificial intelligence (AI) is transforming the healthcare industry by streamlining clinical trials and enabling better use of real-world data.
- The global market for AI-based clinical trial solutions is projected to grow from $2.88 billion in 2025 to $17.40 billion by 2034, driven by a 22.13% annual growth rate.
- Atropos Health’s real-world evidence network of over 300 million patient records enables developers to train and validate AI models for improved patient care and medical innovations.
- AI empowers healthcare providers with advanced tools to make data-driven decisions, improving patient outcomes and overall healthcare efficiency.
AI-based clinical trials market growth
The global market for AI-based clinical trial solutions is on a rapid rise. According to Precedence Research, it is projected to grow from $2.88 billion in 2025 to an impressive $17.40 billion by 2034. This surge, driven by a 22.13% annual growth rate, is fueled by the increasing demand for personalized medicine and the need to manage the complexities of clinical trials more effectively.
North America leads the market, accounting for 44% of the global share in 2024. AI’s role in optimizing trial phases—especially Phase II trials—and its application in oncology are key drivers. Pharmaceutical companies are the primary users, representing 65% of market demand.
AI is transforming drug discovery by dismantling traditional bottlenecks. The process, once taking 10–15 years and $2.6B per drug, is now expedited through AI’s ability to analyze vast datasets, from genomic info to clinical trial data, in record time. Promising compounds can now… pic.twitter.com/Bf3SLleh03
— Bhakta Vaschal Samal (@BhaktaVee) January 3, 2025
Real-world data empowering AI development
AI’s success depends on access to high-quality healthcare data. Atropos Health is tackling this challenge by creating a real-world evidence network of over 300 million patient records. This data pool includes electronic health records, claims, and patient registries, enabling developers to train and validate AI models.
Atropos’ GENEVA OS platform further supports this effort by providing a standardized environment for analyzing real-world data. By leveraging real-world data, companies can build predictive models faster, leading to improved patient care and medical innovations.
Using GENEVA OS, developers can train, test and validate predictive models on standardized, high-quality patient-level data… allowing for rapid model development while adhering to emerging AI assurance standards for transparency, bias detection and accuracy,
Dr. Brigham Hyde, CEO and co-founder of Atropos Health
AI’s role in healthcare is expanding, offering transformative benefits for patients and providers alike. It empowers providers with advanced tools to make data-driven decisions while improving patient outcomes and overall healthcare efficiency.
